



(12)

# Oversættelse af europæisk patent

Patent- og  
Varemærkestyrelsen

(51) Int.Cl.: **A 61 K 38/07 (2006.01)** **A 61 K 38/08 (2019.01)** **A 61 K 38/17 (2006.01)**  
**A 61 P 9/10 (2006.01)** **A 61 P 25/00 (2006.01)**

(45) Oversættelsen bekendtgjort den: **2020-06-15**

(80) Dato for Den Europæiske Patentmyndigheds  
bekendtgørelse om meddelelse af patentet: **2020-05-20**

(86) Europæisk ansøgning nr.: **07796769.3**

(86) Europæisk indleveringsdag: **2007-07-10**

(87) Den europæiske ansøgnings publiceringsdag: **2009-04-08**

(86) International ansøgning nr.: **US2007015747**

(87) Internationalt publikationsnr.: **WO2008008348**

(30) Prioritet: **2006-07-11 US 830189 P** **2006-07-26 US 833572 P**

(84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR**

(73) Patenthaver: **NoNO Inc., 479A Wellington St. W, Toronto, ON M5V 1E7, Canada**

(72) Opfinder: **TYMIANSKI, Michael, 175 Dawlish Avenue, Toronto, Ontario M4N 1H6, Canada**

(74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K, Danmark**

(54) Benævnelse: **PEPTID OG SAMMENSÆTNING DERAF TIL ANVENDELSE VED BEHANDLING AF SLAGTILFÆLDE MED FEBER**

(56) Fremdragne publikationer:  
**EP-A1-1 884 521**  
**WO-A1-2005/061548**  
**WO-A1-2008/109010**  
**WO-A2-2004/045535**  
**US-A1- 2005 059 597**  
**US-A1- 2005 164 933**  
**AARTS MICHELLE ET AL: "Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US LNKD- DOI:10.1126/SCIENCE.1072873, vol. 298, no. 5594, 25 October 2002 (2002-10-25), pages 846-850, XP002476284 ISSN: 0036-8075**  
**LIU Y ET AL: "UNCOUPLING NMDA RECEPTOR - PSD - 95 PROTEIN INTERACTIONS REDUCES INFARCTION IN FOCAL CEREBRAL ISCHEMIA IN RATS" ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, 4 November 2002 (2002-11-04), page 245.3, XP009133058 ISSN: 0190-5295**  
**CUI H ET AL: "PDZ Protein Interactions Underlying NMDA Receptor-Mediated Excitotoxicity and Neuroprotection by PSD-95 Inhibitors" JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US LNKD- DOI:10.1523/JNEUROSCI.1464-07.2007, vol. 27, no. 37, 12 September 2007 (2007-09-12), pages 9901-9915,**

XP002581414 ISSN: 0270-6474

SUN H -S ET AL: "Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat",  
STROKE 20080901 LIPPINCOTT WILLIAMS AND WILKINS USA LNKD- DOI:10.1161/STROKES.107.506048,  
vol. 39, no. 9, 1 September 2008 (2008-09-01), pages 2544-2553, ISSN: 0039-2499

# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

**[0001]** This invention was made with Government support under NIH Grant Number NS048956. The Government may have certain rights in this invention.

## BACKGROUND OF THE INVENTION

**[0002]** Stroke is predicted to affect more than 600,000 people in the United States a year. In a 1999 report, over 167,000 people died from strokes, with a total mortality of 278,000. In 1998, 3.6 billion was paid to just those Medicare beneficiaries that were discharged from short-stay hospitals, not including the long term care for >1,000,000 people that reportedly have functional limitations or difficulty with activities of daily living resulting from stroke (Heart and Stroke Statistical update, American Heart Association, 2002). No therapeutics has yet been approved to reduce brain damage resulting from stroke.

**[0003]** Stroke is characterized by neuronal cell death in areas of ischemia, brain hemorrhage and/or trauma. Cell death is triggered by glutamate over-excitation of neurons, leading to increased intracellular  $\text{Ca}^{2+}$  and increased nitric oxide due to an increase in nNOS (neuronal nitric oxide synthase) activity.

**[0004]** Glutamate is the main excitatory neurotransmitter in the central nervous system (CNS) and mediates neurotransmission across most excitatory synapses. Three classes of glutamate-gated ion channel receptors (N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and Kainate) transduce the postsynaptic signal. Of these, NMDA receptors (NMDAR) are responsible for a significant portion of the excitotoxicity of glutamate. NMDA receptors are complex having an NR1 subunit and one or more NR2 subunits (2A, 2B, 2C or 2D) (see, e.g., McDain, C. and Caner, M. (1994) *Physiol. Rev.* 74:723-760), and less commonly, an NR3 subunit (Chatterton et al. (2002) *Nature* 415:793-798). The NR1 subunits have been shown to bind glycine, whereas NR2 subunits bind glutamate. Both glycine and glutamate binding are required to open the ion channel and allow calcium entry into the cell. The four NR2 receptor subunits appear to determine the pharmacology and properties of NMDA receptors, with further contributions from alternative splicing of the NR1 subunit (Kornau et al. (1995) *Science* 269:1737-40). Whereas NR1 and NR2A subunits are ubiquitously expressed in the brain, NR2B expression is restricted to the forebrain, NR2C to the cerebellum, and NR2D is rare compared to the other types.

**[0005]** Because of the key role of NMDA receptors in the excitotoxicity response, they have been considered as targets for therapeutics. Compounds have been developed that target the ion channel (ketamine, phencyclidine, PCP, MK801, amantadine), the outer channel (magnesium), the glycine binding site on NR1 subunits, the glutamate binding site on NR2 subunits, and specific sites on NR2 subunits (Zinc-NR2A; Ifenprodil, Traxoprodil-NR2B). Among these, the non-selective antagonists of NMDA receptor have been the most neuroprotective agents in animal models of stroke. However, clinical trials with these drugs in stroke and traumatic brain injury have so far failed, generally as a result of severe side effects such as hallucination and even coma. Other criticisms of past animal stroke studies include that the efficacy of many neuroprotectants was determined in mild ischemia models (ischemia-reperfusion instead of permanent ischemia), and under conditions of food deprivation, which can not adequately mimic the more severe human situation. Also, most drugs were administered pre-ischemia whereas human trials necessitate a post-

treatment paradigm (Gladstone et al., 2002; STAIR Committee, 1999).

**[0006]** Another key difference between human stroke and experimental ischemia is that some stroke victims also suffer from aggravating premorbid or comorbid conditions or stroke-related complications. Prominent among these is hyperglycemia (Alvarez-Sabin., 2003), especially in diabetic patients (Paolino, 2005), but also in non-diabetics (Alvarez-Sabin., 2003). However, hyperglycemia is actively avoided in laboratory stroke studies as it is known to exacerbate cerebral infarction (Li, 1997, 1998, 2000, 2001; Farrokhnia, 2005), and experimental animals are routinely fasted to minimize intra-ischemic blood glucose elevations (Elsersy, 2004; Horiguchi, 2003; Belayev, 2005a). Fever is another complication that afflicts some stroke victims, and is an independent predictor of poor outcome (Azzimondi, 1995; Reith, 1996; Boysen, 2001; Ginsberg, 1998). Hyperthermia has long been known to exacerbate both global and focal experimental ischemic injury (Busto, 1987b, 1989a, 1989b; Ginsberg, 1992; Morikawa, 1992; Chen, 1993; Minamisawa, 1990a, 1990b, 1990c; Chen, 1991) and, precisely for this reason, has been strongly avoided in studies of neuroprotective drugs.

**[0007]** The present inventor has reported that postsynaptic density-95 protein (PSD-95) couples NMDARs to pathways mediating excitotoxicity and ischemic brain damage (Aarts et al., Science 298, 846-850 (2002)). This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia. The analysis was performed under conditions of transient ischemia and prior fasting to avoid exacerbating fever and hyperglycemia.

#### SUMMARY OF THE CLAIMED INVENTION

**[0008]** The invention provides a peptide having an amino acid sequence comprising [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L] for use in the treatment, optionally wherein the treatment is prophylactic, of the damaging effect of stroke exacerbated by fever in a human subject having a fever of at least 38 degrees Celsius on initiating treatment. The invention also provides a pharmaceutical composition for use in treating stroke exacerbated by fever in a human subject having a fever of at least 38 degrees Celsius on initiating treatment, which comprises in unit dose from 0.05 to 500 mg, optionally 0.1 to 100 mg, for example 0.5 to 50 mg such as 1 to 20 mg of a peptide as set forth in the claims. The specification describes the use of a peptide having an amino acid sequence comprising T/SXV/L or a peptidomimetic thereof for manufacture of a medicament for treatment of the damaging effect of stroke or other injury to the CNS exacerbated by fever or hyperglycemia.

**[0009]** The invention provides a method of screening a compound that inhibits binding of PSD-95 to NMDAR, comprising: administering the compound to a non-human animal having ischemia and also i) a fever of at least 38 degrees Celsius and/or ii) hyperglycemia; and determining whether the compound reduces infarction volume resulting from the ischemia relative to a control animal not treated with the compound. The invention further provides, as specified by the claims, a method of screening a compound that inhibits binding of PSD-95 to NMDAR, comprising administering the compound to a animal having ischemia exacerbated by hyperthermia and/or hyperglycemia; and determining whether the compound reduces infarction volume resulting from the ischemia relative to a control animal not treated with the compound.

**[0010]** The specification further describes a method for reducing the damaging effect of stroke in a patient having stroke or other injury to the CNS exacerbated by fever or hyperglycemia comprising administering to the an effective amount of a peptide having an amino acid sequence comprising T/S-[X]-V/L, or peptidomimetic thereof, and thereby reducing the damaging effect of the stroke or other injury.

**[0011]** The specification further describes the use of a peptide having an amino acid sequence comprising T/SXV/L or a peptidomimetic thereof in the manufacture of a medicament for treating the damaging effect of stroke or other CNS injury in a patient having fever or hyperglycemia.

**[0012]** The specification further describes the use of a peptide having an amino acid sequence comprising T/SXV/L or a peptidomimetic thereof in the manufacture of a medicament for the prophylactic treatment of the damaging effect of stroke or other CNS injury in a patient with fever or hyperglycemia.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0013]**

**Figure 1.** Effects of ischemia models on core temperature. Animals in A-E were implanted with intra-peritoneal telemetric temperature probes and exposed to the indicated conditions. Gray bars indicate duration of animal surgery. A. Sham procedure (n = 4). B. Sham procedure with administration of Tat-NR2B9c (SDV) (n = 6). C. Pial vessel occlusion (n = 5). D. Permanent MCAO without cage cooling. (n= 8). E. Permanent MCAO with cage cooling using a feedback system (n = 8). CT: Core temperature. Cage: Cage temperature. Symbols in A-E indicate the means + SE of the indicated number of animals. F. Effects of the indicated conditions on temporalis muscle, core, and brain temperature at the indicated times post pMCAO. Core-Saline: animals treated with saline 1h post pMCAO (n = 6). Temporalis-Saline: Concurrent temporalis muscle temperatures from saline treated animals. Core-SDV: animals treated with Tat-NR2B9c (SDV) 1h post pMCAO (n = 6). Brain-SDV: Concurrent direct brain temperature measurements from NR2B9c (SDV)-treated animals.

**Figure 2.** Effect of Tat-NR2B9c (SDV) post-treatment in the permanent pial vessel occlusion model. A. The three sites of pial vessel occlusion. B. Resulting typical infarct in TTC stained brain. C. Effect of the indicated drug and drug concentration on infarct size. Number of animals per group is provided in Table 1. Asterisk: significantly different from both saline and ADA controls (ANOVA, p<0.05). ADA: Tat-NR2B9c (ADA). SDV: Tat-NR2B9c (SDV). D. Representative infarcts in TTC-stained coronal sections from each group.

**Figure 3.** PSD-95 inhibitors do not affect the hyperthermic response following pMCAO. A-E: Core temperatures before, during (gray bars) and following pMCAO surgery in animals treated with the indicated PSD-95 inhibitor at the indicated dose. N = 8 for each group.

**Figure 4.** Representative TTC stained coronal brain sections taken from animals 24h after subjecting them to sham surgery (A) or pMCAO (B-F). Animals in B-F were treated with the indicated PSD-95 inhibitor at the indicated dose at 1h after pMCAO.

**Figure 5.** Reduction of pMCAO infarct volumes by post-treatment with PSD-95 inhibitors. Ai and Aii: Effects of PSD-95 inhibitors on hemispheric (Ai) and cortical (Aii) infarct volumes in the first blinded study. Bi and Bii: Effects of PSD-95 inhibitors on hemispheric (Bi) and cortical (Bii) infarct volumes in the second blinded study. Animals were treated with the PSD-95 inhibitors at the indicated doses at 1h after pMCAO. Asterisks: significantly different from saline controls (ANOVA followed by multiple comparisons using the Bonferroni correction). Inset: study paradigm. Number of animals per group is provided in Table 2.

**Figure 6.** Infarct areas from 8 coronal brain sections from which the volumes in Figure 5 were derived. Each symbol indicates the mean  $\pm$  SE area in a given stereotactic plane for the conditions indicated.

**Figure 7.** A. Composite neurobehavioral scores at 2 and 24 hrs after pMCAO for the indicated conditions. B-G: Plots of animal cage activity before and after the permanent MCAO procedure in the different PSD-95

inhibitor groups. Zero indicates time of MCAO.

## DETAILED DESCRIPTION OF THE INVENTION

### I. DEFINITIONS

**[0014]** A "fusion polypeptide" refers to a composite polypeptide, *i.e.*, a single contiguous amino acid sequence, made up of two (or more) distinct, heterologous polypeptides which are not normally fused together in a single amino acid sequence.

**[0015]** The term "PDZ domain" refers to a modular protein domain of about 90 amino acids, characterized by significant sequence identity (e.g., at least 60%) to the brain synaptic protein PSD-95, the *Drosophila* septate junction protein Discs-Large (DLG), and the epithelial tight junction protein ZO1 (ZO1). PDZ domains are also known as Discs-Large homology repeats ("DHRs") and GLGF repeats. PDZ domains generally appear to maintain a core consensus sequence (Doyle, D. A., 1996, *Cell* 85: 1067-76). Exemplary PDZ domain-containing proteins and PDZ domain sequences disclosed in U.S. Application No. 10/714,537.

**[0016]** The term "PL protein" or "PDZ Ligand protein" refers to a naturally occurring protein that forms a molecular complex with a PDZ-domain, or to a protein whose carboxy-terminus, when expressed separately from the full length protein (e.g., as a peptide fragment of 3-25 residues, e.g. 3, 4, 5, 8, 10, 12, 14 or 16 residues), forms such a molecular complex. The molecular complex can be observed *in vitro* using the "A assay" or "G assay" described, e.g., in U.S. Application No. 10/714,537, or *in vivo*.

**[0017]** The term "NMDA receptor," or "NMDAR," refers to a membrane associated protein that is known to interact with NMDA. The term thus includes the various subunit forms described in the Background Section. Such receptors can be human or non- (e.g., mouse, rat, rabbit, monkey).

**[0018]** A "PL motif" refers to the amino acid sequence of the C-terminus of a PL protein (e.g., the C-terminal 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 20 or 25 contiguous residues) ("C-terminal PL sequence") or to an internal sequence known to bind a PDZ domain ("internal PL sequence").

**[0019]** A "PL peptide" is a peptide of comprising or consisting of, or otherwise based on, a PL motif that specifically binds to a PDZ domain.

**[0020]** The terms "isolated" or "purified" means that the object species (e.g., a peptide) has been purified from contaminants that are present in a sample, such as a sample obtained from natural sources that contain the object species. If an object species is isolated or purified it is the predominant macromolecular (e.g., polypeptide) species present in a sample (*i.e.*, on a molar basis it is more abundant than any other individual species in the composition), and preferably the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, an isolated, purified or substantially pure composition comprises more than 80 to 90 percent of all macromolecular species present in a composition. Most preferably, the object species is purified to essential homogeneity (*i.e.*, contaminant species cannot be detected in the composition by conventional detection methods), wherein the composition consists essentially of a single macromolecular species.

**[0021]** A "peptidomimetic" and refers to a synthetic chemical compound which has substantially the same

structural and/or functional characteristics of a peptide of the invention. The peptidomimetic can contain entirely synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The peptidomimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or inhibitory or binding activity. Polypeptide mimetic compositions can contain any combination of nonnatural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.

**[0022]** The term "specific binding" refers to binding between two molecules, for example, a ligand and a receptor, characterized by the ability of a molecule (ligand) to associate with another specific molecule (receptor) even in the presence of many other diverse molecules, *i.e.*, to show preferential binding of one molecule for another in a heterogeneous mixture of molecules. Specific binding of a ligand to a receptor is also evidenced by reduced binding of a detectably labeled ligand to the receptor in the presence of excess unlabeled ligand (*i.e.*, a binding competition assay).

**[0023]** Statistically significant refers to a p-value that is < 0.05, preferably < 0.01 and most preferably < 0.001.

## II. General

**[0024]** The invention provides, as specified by the claims, peptides useful for reducing the damaging effects of stroke exacerbated by fever. The subsets of patients afflicted with one or both of fever and hyperglycemia (exacerbating factors) have a significantly poorer outcome compared with patients in which these factors are present. The invention is based in part on results described in the examples in which certain peptides were found to reduce infarction volume in a rat model of permanent ischemia notwithstanding severe hyperthermia ( $\geq 39^{\circ}\text{C}$ ) and lack of prior fasting. Surprisingly, subjects with stroke and fever or hyperglycemia can be treated as effectively as subjects not suffering from such comorbid complications. Peptides used in such methods have an amino acid sequence including or based on the PL motif of NMDAR 2B receptor (*i.e.*, PL peptides). Although an understanding of mechanism is not required for practice of the invention, it is believed that such peptides act at least in part by inhibiting interaction between NMDARs with postsynaptic density 95 protein (*i.e.*, PSD-95 inhibitors). The peptides may also inhibit interactions between PSD-95 and nNOS. Unlike glutamate antagonists that have previously failed clinical trials, such peptides can disrupt neurotoxic signaling during ischemia without incurring the negative consequences of loss of NMDAR function.

## III. Peptides and Peptidomimetics

**[0025]** Peptides useful in the invention as specified by the claims inhibit interaction between domain 2 of postsynaptic density-95 protein (PSD-95 d2) containing a PDZ domain (Stathakism, Genomics 44(1):71-82 (1997)) and the C-terminus of NR2B subunit of the neuronal N-methyl-D-aspartate receptor (NMDAR) containing a PL motif (Mandich et al., Genomics 22, 216-8 (1994)). As specified by the claims, such peptides include or are based on a PL motif from the C-terminus of this subunit and have an amino acid sequence comprising [S/T]-X-[V/L] (SEQ ID NO.: 1). This sequence preferably occurs at the C-terminus of the peptides of the invention. Preferred peptides have an amino acid sequence as specified by the claims comprising [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L] (SEQ ID NO.: 2) at their C-terminus. Exemplary peptides comprise: ESDV

(SEQ ID NO.: 3), ESEV (SEQ ID NO.: 4), ETDV (SEQ ID NO.: 5), ETEV (SEQ ID NO.: 6), DTDV (SEQ ID NO.:7), and DTEV (SEQ ID NO.: 8). Two particularly preferred peptides are KLSSIESDV (SEQ ID NO.: 9), and KLSSIETDV (SEQ ID NO.: 10).

**[0026]** Any of the peptides of the invention can be linked, preferably at their N-terminus, to an internalization peptide that facilitates translocation through the plasma membrane of a cell. For example, the HIV TAT internalization peptide YGRKKRRQRRR can be used. An internalization peptide derived from Antennapedia can also be used (see Bonfanti, Cancer Res. 57, 1442-6 (1997)). Two preferred peptides including the HIV Tat internalization peptide are YGRKKRRQRRRKLSSIETDV (SEQ ID NO.: 11, Tat-NR2B9c (TDV)), and YGRKKRRORRKLSSIESDV (SEQ ID NO.: 12, Tat-NR2B9c (SDV)).

**[0027]** Peptides of the invention without an internalization peptide usually have 3-25 amino acids, Peptide lengths (also without an internalization peptide) of 5-10 amino acids, and particularly 9 amino acids are preferred.

**[0028]** Appropriate pharmacological activity of peptides or peptidomimetics can be confirmed, if desired, using the animal model described in the Examples. Optionally, peptides or peptidomimetics can also be screened for capacity to inhibit interactions between PSD-95 and NDMAR 2B using assays described in e.g., US 20050059597.

**[0029]** Useful peptides typically have IC50 values of less than 50uM, 25  $\mu$ M, 10  $\mu$ M, 0.1  $\mu$ M or 0.01  $\mu$ M in such an assay. Preferred peptides typically have an IC50 value of between 0.001-1  $\mu$ M, and more preferably 0.05-0.5 or 0.05 to 0.1  $\mu$ M

**[0030]** Peptides such as those just described can optionally be derivatized (e.g., acetylated, phosphorylated and/or glycosylated) to improve the binding affinity of the inhibitor, to improve the ability of the inhibitor to be transported across a cell membrane or to improve stability. As a specific example, for inhibitors in which the third residue from the C-terminus is S or T, this residue can be phosphorylated before use of the peptide.

**[0031]** Peptides of the invention, optionally fused to internalization domains, can be synthesized by solid phase synthesis or recombinant methods. Peptidomimetics can be synthesized using a variety of procedures and methodologies described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gilman et al. (Eds) John Wiley & Sons, Inc., NY, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234.

#### **IV. Stroke and Related Conditions**

**[0032]** A stroke is a condition resulting from impaired blood flow in the CNS regardless of cause. Potential causes include embolism, hemorrhage and thrombosis. Some neuronal cells die immediately as a result of impaired blood flow. These cells release their component molecules including glutamate, which in turn activates NMDA receptors, which raise intracellular calcium levels, and intracellular enzyme levels leading to further neuronal cell death (the excitotoxicity cascade). The death of CNS tissue is referred to as infarction. Infarction Volume (i.e., the volume of dead neuronal cells resulting from stroke in the brain) can be used as an indicator of the extent of pathological damage resulting from stroke. The symptomatic effect depends both on the volume of an infarction and where in the brain it is located. Disability index can be used as a measure of symptomatic damage, such as the Rankin Stroke Outcome Scale (Rankin, Scott Med J;2:200-15 (1957)) and the Barthel Index. The Rankin Scale is based on assessing directly the global conditions of a patient as follows.

0	No symptoms at all
1	No significant disability despite symptoms; able to carry out all usual duties and activities.
2	Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.
3	Moderate disability requiring some help, but able to walk without assistance
4	Moderate to severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.
5	Severe disability; bedridden, incontinent, and requiring constant nursing care and attention.

**[0033]** The Barthel Index is based on a series of questions about the patient's ability to carry out 10 basic activities of daily living resulting in a score between 0 and 100, a lower score indicating more disability (Mahoney et al., Maryland State Medical Journal 14:56-61 (1965)).

**[0034]** An ischemic stroke refers more specifically to a type of stroke that is caused by blockage of blood flow to the brain. The underlying condition for this type of blockage is most commonly the development of fatty deposits lining the vessel walls. This condition is called atherosclerosis. These fatty deposits can cause two types of obstruction. Cerebral thrombosis refers to a thrombus (blood clot) that develops at the clogged part of the vessel "Cerebral embolism" refers generally to a blood clot that forms at another location in the circulatory system, usually the heart and large arteries of the upper chest and neck. A portion of the blood clot then breaks loose, enters the bloodstream and travels through the brain's blood vessels until it reaches vessels too small to let it pass. A second important cause of embolism is an irregular heartbeat, known as arterial fibrillation. It creates conditions in which clots can form in the heart, dislodge and travel to the brain. Additional potential causes of ischemic stroke are hemorrhage, thrombosis, dissection of an artery or vein, a cardiac arrest, shock of any cause including hemorrhage, and iatrogenic causes such as direct surgical injury to brain blood vessels or vessels leading to the brain or cardiac surgery. Ischemic stroke accounts for about 83 percent of all cases of stroke.

**[0035]** Transient ischemic attacks (TIAs) are minor or warning strokes. In a TIA, conditions indicative of an ischemic stroke are present and the typical stroke warning signs develop. However, the obstruction (blood clot) occurs for a short time and tends to resolve itself through normal mechanisms.

**[0036]** Hemorrhagic stroke accounts for about 17 percent of stroke cases. It results from a weakened vessel that ruptures and bleeds into the surrounding brain. The blood accumulates and compresses the surrounding brain tissue. The two general types of hemorrhagic strokes are intracerebral hemorrhage and subarachnoid hemorrhage. Hemorrhagic stroke result from rupture of a weakened blood vessel. Potential causes of rupture from a weakened blood vessel include a hypertensive hemorrhage, in which high blood pressure causes a rupture of a blood vessel, or another underlying cause of weakened blood vessels such as a ruptured brain vascular malformation including a brain aneurysm, arteriovenous malformation (AVM) or cavernous malformation. Hemorrhagic strokes can also arise from a hemorrhagic transformation of an ischemic stroke which weakens the blood vessels in the infarct, or a hemorrhage from primary or metastatic tumors in the CNS which contain abnormally weak blood vessels. Hemorrhagic stroke can also arise from iatrogenic causes such as direct surgical injury to a brain blood vessel. An aneurysm is a

ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm continues to weaken until it ruptures and bleeds into the brain. An arteriovenous malformation (AVM) is a cluster of abnormally formed blood vessels. A cavernous malformation is a venous abnormality that can cause a hemorrhage from weakened venous structures. Any one of these vessels can rupture, also causing bleeding into the brain. Hemorrhagic stroke can also result from physical trauma. Hemorrhagic stroke in one part of the brain can lead to ischemic stroke in another through shortage of blood lost in the hemorrhagic stroke.

**[0037]** Several other neurological conditions can also result in neurological death through NDMAR-mediated excitotoxicity. These conditions include epilepsy, hypoxia, traumatic injury to the CNS not associated with stroke such as traumatic brain injury and spinal cord injury, Alzheimer's disease and Parkinson's disease. Conditions Exacerbating Stroke

**[0038]** A subset of stroke patients have exacerbating fever and/or hyperglycemia, which are comorbid conditions, that in the absence of treatment by the present methods predispose patients to a poorer outcome than is the case for all stroke patients, particularly stroke patients lacking such an exacerbating comorbidity.

**[0039]** Fever (also known as pyrexia) means an increase in internal body temperature to a level at least 0.5°C above normal (37°C, 98.6°F). In some patients the fever is at least 38, 39 or 40 °C. Fever is related to hyperthermia, which is an acute condition resulting from an increase in body temperature over the body's normal thermoregulatory set-point (due to excessive heat production or insufficient thermoregulation, or an altered thermoregulatory set point or any combination thereof). Fever exacerbates stroke by promoting infarct formation.

**[0040]** Fever, as an exacerbating comorbid condition with stroke, can result from several circumstances. Some patients have an infection before the stroke occurs resulting in fever at the time of the stroke, at the time of treatment, (usually 1-6 hr after the stroke) and usually persisting at least 24 hours after treatment. Other patients do not have fever at the onset of stroke, but develop fever because the stroke affects an area of the brain that controls temperature of the patient. Such a fever can develop between onset of the stroke and initiation of treatment, and can persist for at least 24 hours after treatment. Such a fever can also develop after treatment has begun and persist for a period of at least 24 hours after initiation of treatment. This type of spontaneous fever has been associated with large strokes in humans (Azzimondi *et al.*, 1995; Reith *et al.*, 1996; Ginsberg and Busto, 1998; Boysen and Christensen, 2001). Other patients have fever as a result of being exposed to high temperatures at the time of onset of stroke. Such fever typically persists through initiation of treatment of the patient, but may diminish thereafter.

**[0041]** Hyperglycemia or high blood sugar is a condition in which an excessive amount of glucose circulates in the blood plasma. Blood glucose levels can be measured in either milligrams per deciliter (mg/dL) or in millimoles per liter (mmol/L). In general, normal fasting blood glucose levels range from about 80 to 120 mg/dL or 4 to 7 mmol/L. Fasting blood glucose levels above about 126 mg/dL or 7 mmol/L are hyperglycemic. Although the mechanism by which hyperglycemia exacerbates stroke is controversial, one mechanism is the promotion of tissue acidosis (lowered pH), and/or the activation many intracellular responses such as the activities of protein kinases and protein phosphorylation, intracellular calcium metabolism, and hormone metabolism including glucocorticoids.]

**[0042]** Hyperglycemia as an exacerbating comorbidity with stroke can also result from several circumstances. One circumstance is concurrent presence of diabetes, both type I and II. Although glycemic levels can be controlled to some extent by administration of insulin, diabetes patients are particularly vulnerable to swings in glycemic levels. Hyperglycemia can also be the result of eating a large meal, particularly one rich in simple carbohydrates, before onset of a stroke.

## VI. Methods of Treatment

**[0043]** The peptides or peptidomimetics described above are used to treat patients with stroke exacerbated by fever and/or hyperglycemia, as described above. Treatment is usually initiated as soon as possible after initiation of the stroke. Occasionally, treatment can be initiated at or before onset of stroke in patients known to be at high risk. Risk factors include hypertension, diabetes, family history, smoking, previous stroke, and undergoing surgery. Usually, treatment is first administered within one to six hours after initiation of stroke. Optionally, the temperature of the patient and/or blood glycemic level of the patient is measured before commencing treatment to determine presence or absence of fever and/or hyperglycemia. Presence of diabetes or other metabolic condition disposing the subject to hyperglycemia can also be determined. Optionally, the temperature and blood glycemic level of the patient are monitored at several intervals or at least daily after receiving treatment. Often a single dose of peptide or peptidomimetic of the invention is sufficient. However, multiple doses can also be administered at intervals of 6--24 hr.

**[0044]** The response of the patient to the treatment can be monitored by determining infarction volume before and at various times after treatment. Early ischemia is detectable using MRI diffusion imaging. Combinations of MRI protocols, including perfusion imaging, can be used to determine tissue at risk and predict infarction volume. The methods preferably achieve a reduction in infarction volume of at least 10, 15, 20, 25, 30, 35, 40, or 50% relative to the mean infarction volume in a population of comparable patients not receiving treatment by the methods of the invention. The response of the patient can also be measured from a disability index determined one day to one week after initiating treatment. The patient preferably shows an improvement (i.e., less disability) in disability index of at least 4, 10, 15, 20, 25, 30, 35, 40, or 50% relative to the mean disability index in a population of comparable patients not receiving treatment by the methods of the invention. The patient preferably scores a zero or one on the Rankin stroke index or over 75 on the Barthel index.

## VII. Pharmaceutical Compositions, Dosages and Routes of Administration

**[0045]** The peptides of the invention can be administered in the form of a pharmaceutical composition. Pharmaceutical compositions are manufactured under GMP conditions. Pharmaceutical compositions can, as specified by certain claims, be provided in unit dosage form (i.e., the dosage for a single administration) containing any of the dosages indicated above. Pharmaceutical compositions can be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. In particularly, lyophilized peptides of the invention can be used in the formulations and compositions described below.

**[0046]** Pharmaceutical compositions can be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries that facilitate processing of peptides or peptidomimetics into preparations which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen.

**[0047]** Administration can be parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal or intramuscular. Intravenous administration is preferred.

**[0048]** Pharmaceutical compositions for parenteral administration are preferably sterile and substantially isotonic. For injection, peptides or peptidomimetics can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline or

acetate buffer (to reduce discomfort at the site of injection). The solution can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

**[0049]** Alternatively the peptides or peptidomimetics can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

**[0050]** For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. This route of administration can be used to deliver the compounds to the nasal cavity or for sublingual administration.

**[0051]** For oral administration, the compounds can be formulated by combining the peptides or peptidomimetics with pharmaceutically acceptable carriers as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. For oral solid formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents can be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, solid dosage forms can be sugar-coated or enteric-coated using standard techniques. For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols. Additionally, flavoring agents, preservatives, coloring agents and the like can be added.

**[0052]** In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

**[0053]** Alternatively, other pharmaceutical delivery systems can be employed. Liposomes and emulsions can be used to deliver peptides and peptidomimetics. Certain organic solvents such as dimethylsulfoxide also can be employed, although usually at the cost of greater toxicity. Additionally, the compounds can be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent.

**[0054]** Sustained-release capsules can, depending on their chemical nature, release the peptides or peptidomimetics for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization can be employed.

**[0055]** As the peptides or peptidomimetics of the invention can contain charged side chains or termini, they can be included in any of the above-described formulations as the free acids or bases or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts which substantially retain the biologic activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

**[0056]** The peptides of the invention are used in an amount effective to achieve the intended purpose (e.g., reduction of damage effect of the damaging stroke and related conditions). A therapeutically effective amount means an amount of peptide sufficient to significantly reduce the damage resulting from stroke in a population of patients (or animal models) treated with the peptides of the invention relative to the damage in

a control population of stroke patients (or animal models) not treated with the peptides of the invention. The amount is also considered therapeutically effective if an individual treated patient achieves an outcome more favorable than the mean outcome (determined by infarction volume or disability index) in a control population of comparable patients not treated by methods of the invention. The amount is also considered therapeutically effective if an individual treated patient shows a disability of two or less on the Rankin scale and 75 or more on the Barthel scale. A dosage is also considered therapeutically effective if a population of treated patients shows a significantly improved (i.e., less disability) distribution of scores on a disability scale than a comparable untreated population, see Lees et al 1., N Engl J Med 2006;354:588-600A therapeutically effective regime means a combination of a therapeutically effective dose and a frequency of administration needed to achieve the intended purpose as described above. Usually a single administration is sufficient.

**[0057]** Preferred dosage ranges include 0.001 to 20  $\mu$ mol peptide or peptidomimetic per kg patient body weight, optionally 0.03 to 3  $\mu$ mol peptide or peptidomimetic per kg patient body weight to  $\mu$ mol peptide or peptidomimetic per kg patient body weight within 6 hours of stroke. In some methods, 0.1-20  $\mu$ mol peptide or peptidomimetic per kg patient body weight within 6 hours are administered. In some methods, 0.1-10  $\mu$ mol peptide or peptidomimetic per kg patient body weight is administered within 6 hours, more preferably about 0.3  $\mu$ mol peptide or peptidomimetic per kg patient body weight within 6 hours. In other instances, the dosages range is from 0.005 to 0.5  $\mu$ mol peptide or peptidomimetic per kg patient body weight. Dosage per kg body weight can be converted from rats to humans by dividing by 6.2 to compensate for different surface area to mass ratios. Dosages can be converted from units of moles to grams by multiplying by the molar weight of a peptide. Suitable dosages of peptides or peptidomimetics for use in humans can include 0.001 to 5 mg/kg patient body weight, or more preferably 0.005 to 1 mg/kg patient body weight or 0.05 to 1 mg/kg, or 0.09 to 0.9 mg/kg. In absolute weight for a 75 kg patient, these dosages translate to 0.075-375 mg, 0.375 to 75 mg or 3.75 mg to 75 mg or 6.7 to 67 mg. Rounded to encompass variations in e.g., patient weight, the dosage is usually within 0.05 to 500 mg, preferably 0.1 to 100 mg, 0.5 to 50 mg, or 1-20 mg.

**[0058]** The amount of peptide or peptidomimetic administered depends on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. The therapy can be repeated intermittently while symptoms detectable or even when they are not detectable. The therapy can be provided alone or in combination with other drugs.

**[0059]** Therapeutically effective dose of the present peptides or peptidomimetics can provide therapeutic benefit without causing substantial toxicity. Toxicity of the peptides or peptidomimetics can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD<sub>50</sub> (the dose lethal to 50% of the population) or the LD<sub>100</sub> (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. Peptides or peptidomimetics exhibiting high therapeutic indices are preferred (see, e.g., Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Ch.1, p.1).

## **VIII. Screening Methods**

**[0060]** The invention further provides methods, as specified by the claims, of screening peptides, peptidomimetics and other compounds for activity useful in reducing damaging effects of stroke. The methods are for screening compounds known to inhibit interactions between PSD-95 and NMDAR 2B. Compounds are administered to an animal model of stroke, in which the animal has fever and/or hyperglycemia at the time of administering the compound. Fever can be induced by the ischemic event. For example, the rats subject to permanent focal ischemia described in the Examples spontaneously develop fever probably due to the ischemia affecting an area of the brain affecting brain controlling temperature regulation [Experimental animals can also be caused to have a fever by the introduction of pyrogenic

substances such as bacterial products (endotoxins) that cause them to have a fever, or by increasing the ambient temperature using heating lamps, heating blankets, or other heating devices, to a degree that exceeds the animal's ability to thermoregulate through usual physiological mechanisms such as sweating or, vasodilation. The animals can be subject to hyperglycemia simply by feeding them within 6 or 12 hours of initiating ischemia. After administering compounds to the animals, infarction volume and/or disability index are determined. Infarction volumes are usually determined 24 hr post treatment but can be determined at a later time such as 3,7,14 or 60 days. Disability index can be monitored over time, e.g., at 2 hr post treatment, 24 hr post treatment, one week and one month post treatment. Compounds showing a statistically significant reduction in infarction volume and/or disability index relative to control animals not treated with the compounds are identified as having activity useful for practicing the methods of the invention.

**[0061]** Compounds suitable for screening in the methods include peptides, peptidomimetics and small molecules (i.e., less than 500 Da) known to inhibit interactions of PSD-95 and NMDAR 2B. Other peptides, peptidomimetics and small molecules known to inhibit interactions between other pairs of NMDAR and PDZ domain proteins shown in Table A can also be screened.

**TABLE A: NMDA RECEPTORS WITH PL SEQUENCES**

Name	GI#	C-terminal 20mer sequence	C-terminal 4mer sequence	PL?	internal PL ID
NMDAR1	307302	HPTDITGPLNLSDPSVST VV <u>(SEQ ID NO:13)</u>	STVV <u>(SEQ ID NO:14)</u>	X	AA216
NMDAR1-1	292282	HPTDITGPLNLSDPSVST VV <u>(SEQ ID NO:13)</u>	STVV <u>(SEQ ID NO:14)</u>	X	AA216
NMDAR1-4	472845	HPTDITGPLNLSDPSVST VV <u>(SEQ ID NO:13)</u>	STVV <u>(SEQ ID NO:14)</u>	X	AA216
NMDAR1-3b	2343286	HPTDITGPLNLSDPSVST VV <u>(SEQ ID NO:13)</u>	STVV <u>(SEQ ID NO:14)</u>	X	AA216
NMDAR1-4b	2343288	HPTDITGPLNLSDPSVST VV <u>(SEQ ID NO:13)</u>	STVV <u>(SEQID NO:14)</u>	X	AA216
NMDAR1-2	11 038634	RRAIEREEGQLQLCSRHR RES <u>(SEQ ID NO:15)</u>	HRES <u>(SEQ ID NO:23)</u>		
NMDAR1-3	11038636	RRAIEREEGQLQLCSRHR RES <u>(SEQ ID NO:15)</u>	HRES <u>(SEQ ID NO:23)</u>		
NMDAR2C	6006004	TQGFPGPCTWRRRISSLES EV <u>(SEQ ID NO:16)</u>	ESEV <u>(SEQ ID NO:4)</u>	X	AA180
NMDAR3	560546	FNGSSNGHVYEKLSSIES DV <u>(SEQ ID NO:17)</u>	ESDV <u>(SEQ ID NO:3)</u>	X	AA34.1

Name	GI#	C-terminal 20mer sequence	C-terminal 4mer sequence	PL?	internal PL ID
NMDAR3A	17530176	AVSRKTELEEYQRTSRT CES (SEQ ID NO:18)	TCES (SEQ ID NO:24)		
NMDAR2B	4099612	FNGSSNGHVVYEKLSSIES DV (SEQ ID NO:17)	ESDV (SEQ ID NO:3)	X	
NMDAR2A	558748	LNSCSNRRVYKKMPSIE SDV (SEQ ID NO:19)	ESDV (SEQ ID NO:3)	X	AA34.2
NMDAR2D	4504130	GGDLGTRRGSAHFSSLE SEV (SEQ ID NO:20)	ESEV (SEQ ID NO:4)	X	

**[0062]** Compounds to be screened can be both naturally occurring and synthetic, organic and inorganic, and including polymers (e.g., oligopeptides, polypeptides, oligonucleotides, and polynucleotides), small molecules, antibodies, sugars, fatty acids, nucleotides and nucleotide analogs, analogs of naturally occurring structures (e.g., peptide mimetics, nucleic acid analogs, and the like), and numerous other compounds. Compounds can be prepared from diversity libraries, such as random or combinatorial peptide or non-peptide libraries. Libraries include chemically synthesized libraries, recombinant (e.g., phage display libraries), and *in vitro* translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383. Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, RJB., et al., 1992, J. Mol. Biol. 227:711-718); Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; WO 94/18318 dated August 18, 1994. *In vitro* translation-based libraries include those described in WO 91/05058; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026. By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

## EXAMPLES

## MATERIALS AND METHODS

### PSD-95 Inhibitors

**[0063]** Synthetic peptides (Advanced Protein Technology Centre, Hospital for Sick Kids, Toronto, Ontario or BACHEM California), were designed to inhibit the interactions of NMDARs with the submembrane scaffolding protein PSD-95. PSD-95 binds NMDAR NR2 subunits as well as nNOS through its second PDZ domain (PDZ2; reviewed in Hung, 2002), thus keeping nNOS in a close functional association with NMDARs (Brenman, 1996; Brenman, 1997). The interaction between NMDAR NR2B subunits and the PDZ2 domain of PSD-95 depends on a conserved C-terminus T/SXV motif of NR2B (Kornau, 1995). This interaction can be disrupted by the intracellular introduction of exogenous proteins that contain a 9 residue peptide sequence containing the SXV PDZ-domain binding motif of NR2B (KLSSIESDV (SEQ ID NO.: 9); termed NR2B9c (SDV)) (Aarts, 2002). Here, an additional sequence was synthesized containing the TXV motif (KLSSIETDV (SEQ ID NO.: 10); termed NR2B9c (TDV)), which also interacts with the PDZ2 domain of PSD-95 (Kornau, 1995). These peptides associate with PSD-95 through Type-I PDZ domain interactions (Reviewed in Aarts, 2004). A control peptide was also synthesized, in which the residues in positions 0 and -2 of the C-terminal T/SXV motif were mutated to alanines (KLSSIEADA (SEQ ID NO.: 22; termed NR2B (ADA)), rendering this peptide incapable of binding PSD-95 (Kornau, 1995; Aarts, 2002).

**[0064]** NR2B9c (SDV), NR2B9c (TDV) or NR2B (ADA) on their own are not anticipated to enter cells and therefore, each peptide was fused to a corresponding cell-membrane protein transduction domain (PTD) of the HIV-1-Tat protein (YGRKKRRQRRR (SEQ ID NO.: 21); Tat) to obtain the 20 amino acid peptides Tat-NR2B9c (SDV), Tat-NR2B9c (TDV) and Tat-NR2B (ADA). The Tat PTD transduces cell membranes in a rapid, dose-dependent manner (Schwarze, 1999). This approach was previously used to successfully introduce small peptides and fusion proteins into CNS neurons *in-vitro* and *in-vivo* (Aarts., 2002; Arundine, 2004), and many others by now have shown that protein transduction can be used to deliver systemically administered proteins into the brain during and after stroke (Asoh, 2002; Borsello, 2003; Cao, 2002; Denicourt, 2003; Dietz, 2002; Eum, 2004; Kilic, 2002, 2003; Kim, 2005).

**[0065]** The peptides were prepared daily from lyophilized powder by dissolving them in normal saline to the final desired concentration. They were administered intravenously *via* a slow (4-5 min) injection by individuals blinded to the treatment group.

**[0066]** Experiments were performed in male adult Sprague-Dawley rats weighing 250-300g (Charles River Laboratory, Canada). All procedures conformed to guidelines established by the Canadian Council on Animal Care and with the approval of the University Health Network animal care committee. All animals were housed in groups of 1-2 animals in cages with free access to food and water and in rooms having an ambient temperature of  $20 \pm 1^{\circ}\text{C}$  and 12:12 hr light/dark cycle.

#### **SURGICAL PREPARATION**

**[0067]** Each animal was weighed and then anesthesia was induced. For the permanent pial vessel occlusion model, rats were anesthetized with ketamine (100mg/kg), acepromazine (2 mg/kg), and xylazine (50 mg/kg), supplemented with one third the initial dose as required. For the two permanent middle cerebral artery occlusion (pMCAO) studies, anesthesia was induced with 3.5% halothane in a mixture of nitrous oxide and oxygen (Vol. 2:1) and maintained with 0.8% halothane in the mixture. Rats were endotracheally intubated and mechanically ventilated (60 strokes/min, tidal volume of 30-35ml). A rectal temperature probe was inserted. Polyethylene catheters (PE-50) were introduced into the left femoral artery and vein for blood pressure recording, blood sampling, and drug injection. Mean arterial blood pressure was measured with the use of an indwelling femoral arterial catheter connected to a pressure transducer and was recorded continuously. Serial measurements were made of arterial blood gases, pH, and blood glucose.

## Core, Brain and Temporalis Temperature Measurements and Temperature Control

**[0068]** A day prior to undergoing ischemia, the animals were implanted with intraperitoneal transmitters (E-Mitter; Mini Mitter / Respiromics, Oregon, USA) permitting core temperature (CT) and activity monitoring. Monitoring was performed continuously from 20 hours before, to 24 hours after, the pMCAO (Mini-Mitter VitalView telemetric monitoring software; Mini Mitter / Respiromics, Oregon, USA). During the animal surgery the animals were away from the telemetric receivers, so CT was measured with a rectal probe and maintained at 36.5°C to 37.5°C using a heating lamp or homeothermic blanket. To measure brain temperatures following pMCAO, the right skull was exposed and a 1 mm diameter hole drilled at the following stereotactic coordinates: from bregma, AP 3.3mm, ML 4.0mm, DV 3.0mm. A blunt-tip 19 gauge metal cannula (10 mm length) was inserted to a depth of 5 mm and fixed in place with dental glue. Brain temperature was recorded at 0, 1, 2, 4 and 24h using a small thermocouple probe inserted into the metal cannula. Temporalis muscle temperatures were measured with the same thermocouple probe inserted into the muscle through an 18 gauge needle. Cage temperatures were continuously recorded using an external temperature probe and software (Tektronix WaveStar software; Tektronix, Texas, USA) running on a digital oscilloscope and a separate computer. In some experiments, cage temperature was continuously adjusted based on the animal's CT using a custom-built feedback control setup that drove a Peltier-based cooling device (Igloo KoolMate 18; Texas, USA). The cooling device was automatically activated whenever the animal's CT exceeded a threshold of 37.1°C.

## Permanent Distal Middle Cerebral Artery Pial Vessel Occlusion

**[0069]** This was carried out as described elsewhere (Forder, 2005). In Brief, the right ECA was cannulated with PE 10 polyethylene tubing. The skull was exposed via a midline incision, and a 6- to 8- mm cranial window was made over the right somatosensory cortex (2 mm caudal and 5 mm lateral to bregma). The pial arteries were visualized by injecting small boluses (10- 20  $\mu$ L) of the vital dye patent blue violet (10 mMol/L; Sigma) in normal saline, into the ECA (Fig. 2A). The same three pial arteriolar MCA branches were electrically cauterized and dye injections were repeated to ensure the interruption of flow through the cauterized arterioles. The incision was then closed and the animal returned to its cage and allowed free access to food and water. This permanent ischemia model produces a highly reproducible (Forder, 2005) small infarction that is limited to the cortex underlying the coagulated terminal pial arteries (Fig. 2A,B).

## Permanent Middle Cerebral Artery Occlusion

**[0070]** The left middle cerebral artery was occluded by the intraluminal suture method described by Longa (1989). In brief, the left common carotid artery (CCA) was exposed through a midline neck incision and was dissected free from surrounding nerves and fascia, from its bifurcation to the base of the skull. The occipital artery branches of the external carotid artery (ECA) were then isolated, and these branches were dissected and coagulated. The ECA was dissected further distally and coagulated along with the terminal lingual and maxillary artery branches, which were then divided. The internal carotid artery (ICA) was isolated and carefully separated from the adjacent vagus nerve, and the pterygopalatine artery was ligated close to its origin. The tip of a 4-cm length of 3-0 monofilament nylon suture (Harvard Apparatus) was rounded by burning to achieve a tip diameter of 0.33-0.36 mm and tip length of 0.5-0.6 mm and coated with poly-L-lysine (Belayev *et al.*, 1996). The suture was introduced through the CCA and advanced into the ICA and thence into the circle of Willis (about 18-20mm from the carotid bifurcation), effectively occluding the middle cerebral artery. The silk suture around the CCA was tightened around the intraluminal nylon suture to secure it and

permanently occlude the middle cerebral artery. Sham operated animals underwent the identical surgical procedure, including permanent ligation of the CCA, but without suture insertion to occlude the MCA. The pMCAO procedure was considered to be adequate if the animal's neurobehavioral score (below) exceeded 10 at 2 h after pMCAO. Animals were allowed to recover from anesthesia at room temperature.

#### Neurobehavioral evaluation

**[0071]** Behavioral scoring was performed at 2h and again at 24h after pMCAO. The battery consisted of two tests that have been used previously (Aarts, 2002) to evaluate various aspects of neurological function: the postural reflex test (Bederson, 1986b), and the forelimb placing test (De Ryck, 1989). Neurological function was graded on a scale of 0 to 12 (normal score, 0; maximal score, 12).

#### Infarct Volume Evaluation.

**[0072]** At 24 h after pMCAO the animals were deeply anaesthetized employing halothane inhalation and the brains were quickly removed, sliced into 8 standard coronal sections, and incubated for 30 min in 2% triphenyltetrazolium chloride (TTC; Sigma, St. Louis, USA) in saline at 37°C. This standard technique (Hatfield., 1991; Bederson, 1986a; Joshi, 2004) reveals the infarcted area as a pale, unstained portion of the brain section. Each section was digitally photographed, and the infarcts were then traced onto templates representing the 8 standardized coronal slices. The use of the templates corrects for any brain edema produced by the infarct, allowing for a more accurate determination of infarct volume. Each infarct area was then digitally traced from the templates (MCID Version 6.0, Imaging Research Inc., St. Catharines, Ontario, Canada) and the 8 infarct areas per brain were integrated in order to obtain the volume.

#### Data Analysis

**[0073]** All animal surgery including drug infusions, behavioural assessments and infarct volume determinations were performed by individuals blinded to the treatment group. Exclusions of animals from analysis of the pMCAO data (Results section) were based on pre-established criteria, applied prospectively by individuals blinded to the treatment group. The pre-established exclusion criteria were: all deaths prior to animal sacrifice, failure to maintain CT pre pMCAO and for 10 min post-MCAO at  $37.0 \pm 1.0^\circ\text{C}$ , failure to maintain  $\text{pCO}_2$  between 35 and 45 mmHg or mean arterial blood pressure (MABP) above 100 mm Hg during surgery, failure of the neurobehavioral score to exceed 10 at 2 h after pMCAO, technical surgical complications, and the lack of any basal ganglia infarct on morphological evaluation. Data are expressed in mean  $\pm$  S.E.M. Differences between groups were analyzed using ANOVA followed by multiple comparisons using the Bonferroni correction.

## RESULTS

#### Effects of Overnight Fasting on Blood Glucose

**[0074]** The fasting of animals is common practice in experimental stroke studies (e.g., Belayev, 2005b; Aronowski, 2003; Nakashima, 1995; Kuge, 1995), and can be practiced, in large part, due to the adverse impact of hyperglycemia on the efficacy of neuroprotective compounds. To measure the effect of overnight

fasting on blood glucose, SD rats were either permitted access to water only (fasting period of 16 hours; n = 8; body weight  $278.38 \pm 14.86$ g) or to both food and water overnight (non-fasting; n = 12; body weight  $276.50 \pm 13.69$ g). Blood glucose was determined in the morning. Animals that were permitted free overnight access to both food and water exhibited significantly higher blood glucose levels than animals that had free overnight access to water, but not food ( $5.50 \pm 0.08$  mMol/l vs.  $3.71 \pm 0.21$ mMol/l, respectively;  $t_{18}=9.134$ ;  $p <0.001$ ).

#### Effects of PSD-95 Inhibitors on Core Temperature

**[0075]** Previous experience has shown that the neuroprotective effects of some anti-ischemic drugs might have been, at least in part, related to drug-induced hypothermia (e.g., MK-801; Corbett, 1990). Conversely, if a drug induces hyperthermia, its protective effects might be diminished (Noor, 2005; Memezawa, 1995). To determine whether PSD-95 inhibition affected core temperature (CT), it was measured in rats (n = 6) implanted with telemetric intra-peritoneal temperature monitors. CTs were measured from 20h before until 24h after a single intravenous injection of 3nMole/g of Tat-NR2B9c (SDV), the highest PSD-95 inhibitor dose used in the present study. Changes in CT were compared to those of animals undergoing sham surgery (Methods) with a saline infusion (vehicle, n = 4). Animals in both groups exhibited a mild increase in CT after termination of anesthesia ( $\sim 0.5^\circ\text{C}$  increase) which returned to baseline within 10-15 hours. However, there were no differences in CT at any time point between the sham (vehicle) and peptide-infused animals (Fig. 1A,B). Transient elevations in CT have been noted in rodents after general anesthesia (Hansen *et al.*, 2002; Weinandy *et al.*, 2005), and have been attributed to anaesthetic stress.

#### Effect of pMCAO on Core Temperature.

**[0076]** Spontaneous sustained hyperthermia is a recognized consequence of severe ischemia following MCAO (Roberts-Lewis., 1993; Zhao., 1994; Reglodi., 2000; Legos, 2002; Abraham, 2002, 2003), possibly due to hypothalamic injury (Zhao, 1994), or to early microglial activation in the temperature-regulatory centers of the hypothalamus (Abraham, 2003). To achieve consistent and sustained hyperthermia after pMCAO, the filament used for MCA occlusion was modified according to Abraham, who demonstrated that the degree of post-ischemic hyperthermia and the magnitude of cerebral infarction are related to the size of the occluding filament (Abraham, 2002). pMCAO was induced using a filament with a tip diameter of 0.33-0.36 mm (Methods). This caused the animals' temperature to rise rapidly after pMCAO, peaking at  $\sim 39.5^\circ\text{C}$  approximately 2h after pMCAO and remaining elevated at or above  $39^\circ\text{C}$  for the duration of the 24h observation period (Fig. 1D).

**[0077]** It was next determined whether the spontaneous hyperthermia was the result of the animals' sustaining a defect in their ability to thermoregulate. Using a feedback-controlled cage temperature regulator (Methods) induction of normothermia was attempted in the ischemic animals (n = 8) by cooling the cage whenever their CT exceeded a threshold of  $37.1^\circ\text{C}$  (Fig. 1E). The animals were compared with a cohort which underwent pMCAO, but whose cage was maintained at room temperature (n = 8; Fig. 1D). The hyperthermic response to pMCAO was resistant to cooling by ambient temperature reduction, and the animals maintained a CT  $\geq 39^\circ\text{C}$  even when the cage temperature dropped to  $\sim 8^\circ\text{C}$  (Fig. 1E). Prior studies suggest that blunting this hyperthermic response requires extreme measures, consisting of shaving of large areas of fur, placing the animals at  $4^\circ\text{C}$ , and topically applying 70% alcohol (Reglodi, 2000). Thus it was concluded that the robust and sustained hyperthermia after pMCAO was not due to the inability of the animals to thermoregulate but rather, was due to an alteration in the animal's temperature set-point (fever).

#### Effect of Pial Vessel Occlusion on Core Temperature

**[0078]** As the pMCAO model produced hyperthermia, a permanent ischemia model was sought that would not alter CT so that neuroprotection using PSD-95 inhibitors could be evaluated independently of the hyperthermia produced by pMCAO. To this end a pial vessel occlusion model (Methods) was used that produces a small infarction (Fig. 2A,B) in order to not impact CT. Animals subjected to this ischemic insult (n=5) exhibited no significant changes in CT as compared with sham surgery animals (Fig. 1A,C).

#### **Relationship between Core and Brain Temperature in pMCAO.**

**[0079]** Although brain temperature can be most directly correlated with the extent of ischemic damage (Busto, 1987a, 1987c, 1989b; Dietrich, 1992; Minamisawa, 1990a; Morikawa, 1992), it is unlikely that any systemically-administered drug can affect brain temperature independently of Core temperature. To determine whether core temperature measurements were reflective of brain temperature in this study, some animals that had undergone pMCAO with core temperature monitoring also underwent temperature measurements directly from brain and, in some experiments, from temporalis muscle as a surrogate measure of brain temperature. Core temperature measurements correlated to within 0.5 °C with brain and temporalis muscle temperatures in animals receiving either saline (n = 6; Fig. 1F) or 3nMole/g of Tat-NR2B9c (SDV) (n = 6; Fig. 1F). Thus CT measurements were used for the remainder of the study.

#### **Exclusions from Data Analysis.**

**[0080]** Exclusion criteria (Methods) were applied by individuals blinded to the treatment groups. All exclusions from the pial vessel occlusion study are detailed in Table 1. No animals were excluded after dosing with the PSD-95 inhibitor. Exclusions from analysis of the two pMCAO studies are listed in Table 2. In brief, perioperative mortalities were the main reasons for excluding animals from analysis. Overall mortality rates were 8.7% and 16.4% for animals in the first and second independent pMCAO studies, respectively, with no apparent relationship to the drug infusions or identities. Necropsies revealed that mortalities were primarily associated with subarachnoid and/or brain haemorrhages induced by arterial perforations by the pMCAO filament.

#### **Effect of PSD-95 Inhibitors on Infarction Volume.**

**[0081]** In all experiments, the PSD-95 inhibitors were administered 1h after the onset ischemia, as treatment after stroke onset likely has the most clinical relevance.

**[0082]** The effects of Tat-NR2B9c (SDV) in the pial vessel occlusion model (Fig. 2A) were first evaluated. The animals were treated with vehicle (saline), low (0.3nMole/g) or high (3nMole/g) doses of the PSD-95 inhibitor at 1h after the vessel occlusion. As a further control in this screening study, Tat-NR2B9c (ADA) was used, a peptide incapable of binding PSD-95 (Kornau, 1995; Methods), and which does not affect excitotoxic vulnerability (Aarts, 2002; Arundine *et al.*, 2004) or infarct size (Aarts, 2002). Treatment of the animals with either vehicle or Tat-NR2B9c (ADA) resulted in infarcts localized to the cortex underlying the pial vessel occlusion, occupying about 9-10% of the hemisphere volume (Fig. 2B). Treatment of the animals with Tat-NR2B9c (SDV) (3nMole/g) reduced the infarcts by about 60% (Fig. 2C,D).

**[0083]** Next, the PSD-95 inhibitors in pMCAO was used. All of the animals that underwent pMCAO exhibited hyperthermia to the same degree, with CT exceeding 39.5°C in the first 8h, and remaining at about 39°C thereafter (Fig. 3A-E). Injection of the PSD-95 inhibitors had no impact on the hyperthermic response post pMCAO as there were no significant differences between the treatment groups in either the peak or the mean temperature elevation (ANOVA,  $p > 0.15$  for each).

**[0084]** Animals that had undergone pMCAO without treatment sustained large hemispheric infarcts that, at 24h, occupied the majority of the cortical surface and deep structures (Fig. 4B). However, treatment with the PSD-95 inhibitor Tat-NR2B9c (SDV) 1h after pMCAO (0.3-3.0 nM/g) attenuated the total infarct volume (e.g., Fig. 4C,D) by as much as 40% (Fig. 5A<sub>i</sub>), with the effects being most pronounced in the cortical component of the infarct (~45% cortical infarct reduction; Fig. 5A<sub>ii</sub>). The reduction in tissue infarction was observable in all stereotactic planes used to quantify the infarct volumes (Figs 4C,D, 6A<sub>i</sub>,A<sub>ii</sub>).

**[0085]** Neuroprotection by the Tat-NR2B9c (SDV) peptide has been reported by us previously in-vitro (Aarts, 2002; Arundine., 2004) and in-vivo using a model of transient, reversible MCAO (Aarts, 2002). The terminal amino acids in the -0 and -2 positions are critical, and mutation of even one residue prevents or reduces the association of the NR2B C-terminus with PSD-95 (Bassand, 1999). However, it is predicted that peptides ending with the C-terminal IDV consensus sequence should also bind similar protein targets, including PSD-95 (Kornau, 1995, 1997; Niethammer, 1996; Bassand, 1999). If so, then they can exhibit similar neuroprotective effects, though this has never been determined in any disease model. To test this hypothesis, Tat-NR2B9c (IDV) was used at 0.3mM/g and at 3.0nM/g in the same study and under the same conditions as Tat-NR2B9c (SDV). As shown in Figs. 4E,F, 5A<sub>i</sub>,A<sub>ii</sub>, and 6A<sub>i</sub>,A<sub>ii</sub>, this peptide also reduced hemispheric infarction volume by ~35%, and cortical infarction by 40-45%.

**[0086]** Next, the reproducibility of the novel findings arising from the first study was evaluated. A second, confirmatory, study was carried out similarly to the first. The confirmatory study focused on replicating the effects of the lower concentration of the Tat-NR2B9c (SDV) peptide, and the effects of the Tat-NR2B9c (IDV) peptides. As surgical technique is a key variable in animal stroke models, the surgery in the two independent studies was performed by different, blinded, surgeons. As in the first study, all peptides were administered at 1h after pMCAO. The team conducting the confirmatory study was blinded to the results of the first study.

**[0087]** The confirmatory study yielded similar results to the first, with both the Tat-NR2B9c (SDV) and Tat-NR2B9c (IDV) peptides having had a similar effect on reducing both hemispheric and cortical infarction volumes (Figs. 5B<sub>i</sub>,B<sub>ii</sub>, 6B<sub>i</sub>,B<sub>ii</sub>).

#### **Effect of PSD-95 Inhibitors on Cage Activity and on Neurobehavioral Scores.**

**[0088]** A disadvantage of the pMCAO intraluminal thread occlusion model combined with hyperthermia and in unfasted animals is that the experimental animals suffer from an extensive brain insult causing severe neurological deficits (composite neurological score >11 in untreated animals; Fig. 7A). Unlike in transient MCAO, in which this score improves spontaneously by 24h (Belayev., 2001; Aarts, 2002), the untreated animals in this series of experiments remained profoundly impaired (24h composite neurological scores of ~11). The animals treated with the PSD-95 inhibitors showed a trend towards improved neurological scores 24h after pMCAO, but these results did not reach statistical significance (paired Student's t-test,  $P>0.05$ ; Fig. 7A). However, telemetric monitoring of cage activity (Colbourne, 1999; Barber, 2004) revealed that by 24h animals treated with the PSD-95 inhibitors had similar levels of cage activity as compared with shams (Fig. 7B) and pre-MCAO levels (Fig 7D-G), whereas the activity in the untreated animals dropped off (Fig. 7C). Longer post-pMCAO recovery times can be necessary to fully evaluate neurological recovery after this

profound type of ischemic injury. However, this was not pursued in the present study due to concerns about the longer-term survivability of untreated animals.

### Bibliography

#### **[0089]**

Aarts (2002) *Science* 298:846-850.

Aarts (2004) *Curr Mol Med* 4:137-147.

Abraham (2002) *Exp Brain Res* 142:131-138.

Abraham (2003) *Exp Brain Res* 153:84-91.

Alvarez-Sabin (2003) *Stroke* 34:1235-1241.

Aronowski (2003) *Stroke* 34:1246-1251.

Arundine (2004) *J Neurosci* 24:8106-8123.

Asoh (2002) *Proc Natl Acad Sci U S A* 99:17107-17112.

Azzimondi (1995) *Stroke* 26:2040-2043.

Barber (2004) *Stroke* 35:1720-1725.

Bassand (1999) *Eur J Neurosci* 11:2031-2043.

Beckman (1996) *Chem Res Toxicol* 9:836-844.

Beckman (1996) 271:C1424-C1437.

Bederson (1986a) *Stroke* 17:1304-1308.

Bederson (1986b) *Stroke* 17:472-476.

Belayev (1996) *Stroke* 27:1616-1622.

Belayev (2005a) *Stroke* 36:1071-1076.

Belayev (2001) *Stroke* 32:553-560.

Belayev (2005b) *Stroke* 36:326-331.

Borsello (2003) *Nat Med* 9:1180-6

Boysen (2001) *Stroke* 32:413-417.

Brenman (1997) *Current Opin Neurobiol* 7:374-378.

Brenman (1996) *Cell* 84:757-767.

Busto (1987a) *J Cereb Blood Flow Metab* 7:729-738.

Busto (1989a) *Neurosci Lett* 101:299-304.

Busto (1989b) *Stroke* 20:1113-1114.

Busto (1987b) Cereb Blood Flow Metab 7:729-738.

Busto (1987c) J Cereb Blood Flow Metab 7:729-738.

Cao (2002) J Neurosci 22:5423-5431.

Chen (1991) Neurology 41:1133-1135.

Chen (1993) J Cereb Blood Flow Metab 13:389-394.

Colbourne (1999) J Cereb Blood Flow Metab 19:742-749.

Corbett (1990) Brain Res 514:300-304.

Crow (1996) Adv Exp Med Biol 387:147-161.

Davis (1997) Lancet 349:32.

Davis (2000) Stroke 31:347-354.

Dawson (1993) J Neurosci 13:2651-2661.

Dawson (1991) Proc Natl Acad Sci USA 88:6368-6371.

De Keyser (1999) Trends Neurosci 22:535-540.

De Ryck (1989) Stroke 20:1383-1390.

Denicourt (2003) Trends Pharmacol Sci 24:216-218.

Dietrich (1992) J Neurotrauma 9:Suppl 2:S475-85.

Dietz (2002) Mol Cell Neurosci 21:29-37.

Dirnagl (1999) Trends Neurosci 22:391-397.

Donnan (2005) Stroke 36:2326.

Elsersy (2004) Anesthesiology 100:1160-1166.

Eum (2004) Free Radic Biol Med 37:1656-1669.

Farrokhnia (2005) Acta Neurol Scand 112:81-87.

Fisher (2005) Stroke 36:2324-2325.

Forder (2005) Am J Physiol Heart Circ Physiol 288:H1989-H1996.

Ginsberg (1998) Stroke 29:529-534.

Ginsberg (1992) Cerebrovasc Brain Metab Rev 4:189-225.

Gladstone (2002) Stroke 33:2123-2136.

Hansen (2002) Lab Anim 36:144-152.

Hatfield (1991) Neuropathol Appl Neurobiol 17:61-67.

Horiguchi (2003) Stroke 34:1015-1020.

Hung (2002) J Biol Chem 277:5699-5702.

Ikonomidou (2000) Proc Natl Acad Sci U S A 97:12885-12890.

Ikonomidou (2002) Lancet Neurology 383-386.

Joshi (2004) Brain Res Brain Res Protoc 13:11-17.

Kaste (2005) Stroke 36:2323-2324.

Kilic (2002) Ann Neurol 52:617-622.

Kilic (2003) Stroke 34:1304-1310.

Kim (2005) Mol Cells 19:88-96.

Kornau (1995) Science 269:1737-1740.

Kornau (1997) Current Opin Neurobiol 7:368-373.

Kuge (1995) Stroke 26:1655-1657.

Lees (2000) Lancet 355:1949-1954.

Legos (2002) J Neurosci Methods 113:159-166.

Li (2001) 21:568-576.

Li (2000) Stroke 31:183-192.

Li (1997) Acta Physiol Scand 161:567-580.

Li (1998) Brain Res 782:175-183.

Longa (1989) Stroke 20:84-91.

Memezawa (1995) Brain Res 670:48-52.

Migaud (1998) Nature 396:433-439.

Minamisawa (1990a) Stroke 21:758-764.

Minamisawa (1990b) J Cereb Blood Flow Metab 10:365-374.

Minamisawa (1990c) TAnn Neurol 28:26-33.

Morikawa (1992) J Cereb Blood Flow Metab 12:380-389.

Morris (1999) J Neurosurg 91:737-743.

Nakashima (1995) Anesthesiology 82:1199-1208.

Niethammer (1996) J Neurosci 16:2157-2163.

Noor (2005) Stroke 36:665-669.

Paolino (2005) J Neurosci Nurs 37:130-135.

Reglodi (2000) Exp Neurol 163:399-407.

Reith (1996) Lancet 347:422-425.

Roberts-Lewis (1993) J Neurochem 61:378-381.

Rothman (1995) Trends Neurosci 18:57-58.

Rothman (1987) Trends Neurosci 10:299-302.

Sattler (1999) Science 284:1845-1848.

Schwarze (1999) Science 285:1569-1572.

Sheng (2001) Proc Natl Acad Sci U S A 98:7058-7061.

STAIR Committee (1999) Stroke 30:2752-2758.

Walters (2005) Cerebrovasc Dis 20:304-309.

Weinandy (2005) Lab Anim 39:200-208.

Ye (1996) Methods Enzymol 269:201-209.

Zhang (1994) Science 263:687-689.

Zhao (1994) Brain Res 649:253-259.

**[0090]** The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

**Table 1: Mortalities and Exclusions from Pial Vessel Occlusion Study:**

Group	Animals entered	Surgical Deaths*	Post-op Deaths	Surgical Technique**	Number analyzed
SALINE	9	2	0	1	6
Tat-NR2B9c (SDV) (0.3nMole/g)	9	1	0	1	7
Tat-NR2B9c (SDV) (3.0nMole/g)	9	0	0	2	7

Animals excluded due to surgical deaths\* or due to difficulties with surgical technique\*\* (difficulty obtaining clean pial cauterization) were all excluded before the drug infusion. There were no exclusions after dosing.

**Table 2: Mortalities and Exclusions from pMCAO Study**

Surgeon # (1/2)	Animals entered	Surgical Deaths	Post-op Deaths**	excluded because 2h Neuro-score <=10	MABP < 100 mm Hg during surgery	pCO <sub>2</sub> <35 or >45	CT <36 or >38°C pre and 10 min after pMCAO	No basal ganglia infarcts	Number analyzed
SALINE	19 / 11	1* / 0	2 / 3***	0 / 0	0 / 0	0 / 0	0 / 0	2 / 0	14 / 8
Tat-NR2B9c (SDV)	10 / 9	0 / 0	1 / 1	0 / 0	1 / 0	0 / 0	0 / 0	1 / 0	7 / 8

Surgeon # (1/2)									
Group	Animals entered	Surgical Deaths	Post-op Deaths**	excluded because 2h Neuro-score <=10	MABP < 100 mm Hg during surgery	pCO <sub>2</sub> <35 or >45	CT <36 or >38°C pre and 10 min after pMCAO	No basal ganglia infarcts	Number analyzed
(0.3nMole/lq)									
Tat-NR2B9c (SDV) (3.0nMole/q)	9	0	1	0	0	0	0	0	8
Tat-NR2B9c (TDV) (0.3nMole/g)	9 / 10	0 / 0	0 / 2	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	9 / 8
Tat-NR2B9c (TDV) (3.0 nMole/g)	10 / 11	0 / 0	0 / 3	0 / 0	2 / 0	0 / 0	0 / 0	0 / 0	8 / 8
Sham Surgery	4	0	0	0	0	0	0	0	4
pMCAO with feedback Cooling	8	0	0	0	0	0	0	0	8

The two numbers in each cell (X/Y) represent animal numbers for surgeons from pMCAO study #1 and #2, respectively.

\* Expired before MCAO, during arterial catheterisation

\*\* Necropsy revealed brain/subarachnoid hemorrhage likely incurred from MCAO filament insertion.

\*\*\* One animal euthanized due to respiratory problems 5h post pMCAO surgery. Necropsy revealed tracheal injury related to intubation.

Table 3-1

Physiological Parameters of All Groups from 1 <sup>st</sup> Study.						
Groups	Control	SDV 0.3 nmol/g	SDV 3 nmol/g	TDV 0.3 nmol/g	TDV 3 nmol/g	Sham
N	8	8	8	9	8	4
BW (g)	275.25 ± 7.83	291.13 ± 4.30	302.87 ± 8.22	296.44 ± 5.15	300.75 ± 4.67	291.25 ± 4.05
24hrs	248.75 ± 8.04	250.00 ± 3.55	242.80 ± 4.12	254.63 ± 2.73	259.38 ± 4.86	277.25 ± 4.71
NS@2hrs	11.25 ± 0.25	10.50 ± 0.27	10.88 ± 0.13	11.00 ± 0.00	11.25 ± 0.16	0
24hrs	11.00 ± 0.33	10.37 ± 0.26	10.00 ± 0.42	10.55 ± 0.41	10.37 ± 0.42	0
MABP (mmHg)	126.13 ± 5.80	119.63 ± 5.14	126.75 ± 4.39	126.00 ± 5.54	123.63 ± 6.27	108.75 ± 3.88
10min	139.38 ± 4.88	136.75 ± 4.85	134.38 ± 7.42	121.44 ± 5.23	140.63 ± 7.64	132.25 ± 8.44
70min	134.88 ± 3.60	139.38 ± 5.14	103.38 ± 5.06	129.44 ± 6.54	102.13 ± 2.39	120.75 ± 5.59
pH	7.43 ± 0.01	7.42 ± 0.01	7.44 ± 0.01	7.42 ± 0.02	7.44 ± 0.01	7.43 ± 0.01

Physiological Parameters of All Groups from 1 <sup>st</sup> Study.						
Groups	Control	SDV 0.3 nmol/g	SDV 3 nmol/g	TDV 0.3 nmol/g	TDV 3 nmol/g	Sham
10min	7.42 ± 0.01	7.42 ± 0.01	7.43 ± 0.01	7.44 ± 0.01	7.43 ± 0.01	7.43 ± 0.01
70min	7.41 ± 0.01	7.43 ± 0.01	7.41 ± 0.01	7.41 ± 0.01	7.40 ± 0.01	7.42 ± 0.01
pCO <sub>2</sub> (mmHg)	38.5 ± 1.27	37.5 ± 0.42	37.38 ± 0.78	38.11 ± 0.81	39.75 ± 0.70	39.25 ± 0.63
10min	40.00 ± 0.91	41.38 ± 0.98	40.75 ± 1.03	39.33 ± 0.73	40.25 ± 0.99	38.25 ± 0.25
70min	39.88 ± 1.13	39.00 ± 1.35	37.00 ± 0.53	38.67 ± 0.93	40.38 ± 0.84	38.50 ± 1.50
pO <sub>2</sub> (mmHg)	142.13 ± 4.80	137.75 ± 7.18	130.63 ± 5.63	131.44 ± 9.11	130.63 ± 6.24	130.25 ± 15.39
10min	140.00 ± 5.83	132.38 ± 6.77	129.75 ± 4.67	124.22 ± 6.34	136.00 ± 2.57	122.00 ± 5.67
70min	136.38 ± 4.93	139.38 ± 7.15	136.13 ± 5.28	137.67 ± 4.75	132.25 ± 4.65	125.5 ± 8.58

BW - body weight; NS - neurobehavior score.  
Mean ± SEM

Table 3-2

Physiological Parameters of All Groups from 2 <sup>nd</sup> Study.				
Groups	Control	SDV 0.3 nmol/g	TDV 0.3 nmol/g	TDV 3 nmol/g
N	8	8	8	8
BW (g)	293.75 ± 4.07	287.75 ± 6.84	293.50 ± 2.28	296.25 ± 3.25
NS@2hrs	10.75 ± 0.16	10.86 ± 0.13	10.63 ± 0.18	10.60 ± 0.24
24hrs	10.88 ± 0.13	10.43 ± 0.28	10.63 ± 0.18	11.00 ± 0.00
MABP (mmHg)	116.00 ± 5.29	114.50 ± 3.76	119.00 ± 4.11	124.13 ± 6.29
10min	134.00 ± 8.76	134.38 ± 4.16	140.50 ± 4.69	146.63 ± 4012
70min	137.25 ± 5.52	125.75 ± 4.94	129.25 ± 8.09	130.25 ± 12.26
pH	7.39 ± 0.01	7.39 ± 0.01	7.38 ± 0.02	7.41 ± 0.01
10min	7.40 ± 0.01	7.41 ± 0.01	7.38 ± 0.01	7.38 ± 0.02
70min	7.39 ± 0.01	7.41 ± 0.02	7.41 ± 0.01	7.39 ± 0.02
pCO <sub>2</sub> (mmHg)	40.13 ± 1.19	39.13 ± 1.25	39.25 ± 1.06	38.63 ± 1.05
10min	40.88 ± 0.93	38.63 ± 0.89	42.75 ± 0.59	37.50 ± 0.80
70min	39.13 ± 1.25	39.50 ± 1.22	41.75 ± 1.13	40.88 ± 1.42
pO <sub>2</sub> (mmHg)	119.13 ± 7.83	142.75 ± 4.34	133.13 ± 5.15	141.13 ± 10.44
10min	121.25 ± 6.09	137.75 ± 5.55	132.00 ± 4.92	120.13 ± 6.53
70min	120.50 ± 3.01	126.38 ± 4.79	121.00 ± 4.39	124.63 ± 4.44

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

#### Patent documents cited in the description

- [US714537 \[0015\] \[0016\]](#)
- [US20050059597A \[0028\]](#)
- [WO9320242A \[0062\]](#)
- [WO9418318A \[0062\]](#)
- [WO9105058A \[0062\]](#)

#### Non-patent literature cited in the description

- **MCDAIN, C.**[CANER, M.](#)*Physiol. Rev.*, 1994, vol. 74, 723-760 [\[0004\]](#)
- **CHATTERTON**[Nature](#), 2002, vol. 415, 793-798 [\[0004\]](#)
- **KORNAU** et al.*Science*, 1995, vol. 269, 1737-40 [\[0004\]](#)
- **GLADSTONE** et al.*STAIR Committee*, 1999, [\[0005\]](#)
- **AARTS** et al.*Science*, 2002, vol. 298, 846-850 [\[0007\]](#)
- **DOYLE, D. A.***Cell*, 1996, vol. 85, 1067-76 [\[0015\]](#)
- **STATHAKISM***Genomics*, 1997, vol. 44, 171-82 [\[0025\]](#)
- **MANDICH** et al.*Genomics*, 1994, vol. 22, 216-8 [\[0025\]](#)
- **BONFANTIC***Cancer Res.*, 1997, vol. 57, 1442-6 [\[0026\]](#)
- **Organic Syntheses Collective Volumes**[AL-OBEIDI](#) et al.*Mol. Biotechnol.*John Wiley & Sons, Inc.19980000vol. 9, 205-223 [\[0031\]](#)
- **HRUBY***Curr. Opin. Chem. Biol.*, 1997, vol. 1, 114-119 [\[0031\]](#)
- **OSTERGAARD***Mol. Divers.*, 1997, vol. 3, 17-27 [\[0031\]](#)
- **OSTRESH***Methods Enzymol.*, 1996, vol. 267, 220-234 [\[0031\]](#)
- **RANKIN***Scott Med J*, 1957, vol. 2, 200-15 [\[0032\]](#)
- **MAHONEY** et al.*Maryland State Medical Journal*, 1965, vol. 14, 56-61 [\[0033\]](#)
- **LEESN***Engl J Med*, 2006, vol. 354, 588-600A [\[0056\]](#)
- **FINGL** et al.*The Pharmacological Basis of Therapeutics*197500001- [\[0059\]](#)
- **FODOR** et al.*Science*, 1991, vol. 251, 767-773 [\[0062\]](#)
- **HOUGHTEN** et al.*Nature*, 1991, vol. 354, 84-86 [\[0062\]](#)
- **LAM** et al.*Nature*, 1991, vol. 354, 82-84 [\[0062\]](#)
- **MEDYNSKI***Bio/Technology*, 1994, vol. 12, 709-710 [\[0062\]](#)
- **GALLOP** et al.*J. Medicinal Chemistry*, 1994, vol. 37, 91233-1251 [\[0062\]](#)
- **OHLMEYER** et al.*Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 10922-10926 [\[0062\]](#)
- **ERB** et al.*Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 11422-11426 [\[0062\]](#)
- **HOUGHTEN** et al.*Biotechniques*, 1992, vol. 13, 412- [\[0062\]](#)
- **JAYAWICKREME** et al.*Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 1614-1618 [\[0062\]](#)
- **SALMON** et al.*Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 11708-11712 [\[0062\]](#)
- **BRENNERLERNER***Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 5381-5383 [\[0062\]](#)
- **SCOTTSMITH***Science*, 1990, vol. 249, 386-390 [\[0062\]](#)
- **DEVLIN** et al.*Science*, 1990, vol. 249, 404-406 [\[0062\]](#)

- CHRISTIAN, RJB. et al. *J. Mol. Biol.*, 1992, vol. 227, 711-718 [0062]
- LENSTRAJ. *Immunol. Meth.*, 1992, vol. 152, 149-157 [0062]
- KAY et al. *Gene*, 1993, vol. 128, 59-65 [0062]
- MATTHEAKIS et al. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 9022-9026 [0062]
- BUNIN et al. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 4708-4712 [0062]
- SIMON et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 9367-9371 [0062]
- OSTRESH et al. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 11138-11142 [0062]
- AARTSScience, 2002, vol. 298, 846-850 [0089]
- AARTSCurr Mol Med, 2004, vol. 4, 137-147 [0089]
- ABRAHAMExp Brain Res, 2002, vol. 142, 131-138 [0089]
- ABRAHAMExp Brain Res, 2003, vol. 153, 84-91 [0089]
- ALVAREZ-SABINStroke, 2003, vol. 34, 1235-1241 [0089]
- ARONOWSKIStroke, 2003, vol. 34, 1246-1251 [0089]
- ARUNDINEJ Neurosci, 2004, vol. 24, 8106-8123 [0089]
- ASOHProc Natl Acad Sci U S A, 2002, vol. 99, 17107-17112 [0089]
- AZZIMONDIStroke, 1995, vol. 26, 2040-2043 [0089]
- BARBERStroke, 2004, vol. 35, 1720-1725 [0089]
- BASSANDEur J Neurosci, 1999, vol. 11, 2031-2043 [0089]
- BECKMANChem Res Toxicol, 1996, vol. 9, 836-844 [0089]
- BEDERSONStroke, 1986, vol. 17, 1304-1308 [0089]
- BEDERSONStroke, 1986, vol. 17, 472-476 [0089]
- BELAYEVStroke, 1996, vol. 27, 1616-1622 [0089]
- BELAYEVStroke, 2005, vol. 36, 1071-1076 [0089]
- BELAYEVStroke, 2001, vol. 32, 553-560 [0089]
- BELAYEVStroke, 2005, vol. 36, 326-331 [0089]
- BORSELLONNat Med, 2003, vol. 9, 1180-6 [0089]
- BOYSENStroke, 2001, vol. 32, 413-417 [0089]
- BRENNMANCurrent Opin Neurobiol, 1997, vol. 7, 374-378 [0089]
- BRENNMANCell, 1996, vol. 84, 757-767 [0089]
- BUSTOJ Cereb Blood Flow Metab, 1987, vol. 7, 729-738 [0089] [0089]
- BUSTONeurosci Lett, 1989, vol. 101, 299-304 [0089]
- BUSTOStroke, 1989, vol. 20, 1113-1114 [0089]
- BUSTOCereb Blood Flow Metab, 1987, vol. 7, 729-738 [0089]
- CAOJ Neurosci, 2002, vol. 22, 5423-5431 [0089]
- CHENNNeurology, 1991, vol. 41, 1133-1135 [0089]
- CHENJ Cereb Blood Flow Metab, 1993, vol. 13, 389-394 [0089]
- COLBOURNEJ Cereb Blood Flow Metab, 1999, vol. 19, 742-749 [0089]
- CORBETTBrain Res, 1990, vol. 514, 300-304 [0089]
- CROWAdv Exp Med Biol, 1996, vol. 387, 147-161 [0089]
- DAVISLancet, 1997, vol. 349, 32- [0089]
- DAVISStroke, 2000, vol. 31, 347-354 [0089]
- DAWSONJ Neurosci, 1993, vol. 13, 2651-2661 [0089]
- DAWSONProc Natl Acad Sci USA, 1991, vol. 88, 6368-6371 [0089]
- DE KEYSERTrends Neurosci, 1999, vol. 22, 535-540 [0089]
- DE RYCKStroke, 1989, vol. 20, 1383-1390 [0089]
- DENICOURTTrends Pharmacol Sci, 2003, vol. 24, 216-218 [0089]
- DIETRICHJ Neurotrauma, 1992, vol. 9, 2475-85 [0089]
- DIETZMol Cell Neurosci, 2002, vol. 21, 29-37 [0089]
- DIRNAGLTrends Neurosci, 1999, vol. 22, 391-397 [0089]
- DONNANStroke, 2005, vol. 36, 2326- [0089]

- **ELSERSY** Anesthesiology, 2004, vol. 100, 1160-1166 [0089]
- **EUM** Free Radic Biol Med, 2004, vol. 37, 1656-1669 [0089]
- **FARROKHNI** A Acta Neurol Scand, 2005, vol. 112, 81-87 [0089]
- **FISHER** Stroke, 2005, vol. 36, 2324-2325 [0089]
- **FORDER** Am J Physiol Heart Circ Physiol, 2005, vol. 288, H1989-H1996 [0089]
- **GINSBERG** Stroke, 1998, vol. 29, 529-534 [0089]
- **GINSBERG** Cerebrovasc Brain Metab Rev, 1992, vol. 4, 189-225 [0089]
- **GLADSTONE** Stroke, 2002, vol. 33, 2123-2136 [0089]
- **HANSEN** Lab Anim, 2002, vol. 36, 144-152 [0089]
- **HATFIELD** Neuropathol Appl Neurobiol, 1991, vol. 17, 61-67 [0089]
- **HORIGUCHI** Stroke, 2003, vol. 34, 1015-1020 [0089]
- **HUNG** J Biol Chem, 2002, vol. 277, 5699-5702 [0089]
- **IKONOMIDOU** Proc Natl Acad Sci U S A, 2000, vol. 97, 12885-12890 [0089]
- **IKONOMIDOU** Lancet Neurology, 2002, 383-386 [0089]
- **JOSHIB** Brain Res Brain Res Protoc, 2004, vol. 13, 11-17 [0089]
- **KASTE** Stroke, 2005, vol. 36, 2323-2324 [0089]
- **KILIC** Ann Neurol, 2002, vol. 52, 617-622 [0089]
- **KILIC** Stroke, 2003, vol. 34, 1304-1310 [0089]
- **KIM** Mol Cells, 2005, vol. 19, 88-96 [0089]
- **KORNAU** Science, 1995, vol. 269, 1737-1740 [0089]
- **KORNAU** Current Opin Neurobiol, 1997, vol. 7, 368-373 [0089]
- **KUGE** Stroke, 1995, vol. 26, 1655-1657 [0089]
- **LEES** Lancet, 2000, vol. 355, 1949-1954 [0089]
- **LEGOS** J Neurosci Methods, 2002, vol. 113, 159-166 [0089]
- **LI** Stroke, 2000, vol. 31, 183-192 [0089]
- **LI** Acta Physiol Scand, 1997, vol. 161, 567-580 [0089]
- **LIB** Brain Res, 1998, vol. 782, 175-183 [0089]
- **LONGA** Stroke, 1989, vol. 20, 84-91 [0089]
- **MEMEZAWA** Brain Res, 1995, vol. 670, 48-52 [0089]
- **MIGAUD** Nature, 1998, vol. 396, 433-439 [0089]
- **MINAMISAWA** Stroke, 1990, vol. 21, 758-764 [0089]
- **MINAMISAWA** J Cereb Blood Flow Metab, 1990, vol. 10, 365-374 [0089]
- **MINAMISAWA** Ann Neurol, 1990, vol. 28, 26-33 [0089]
- **MORIKAWA** J Cereb Blood Flow Metab, 1992, vol. 12, 380-389 [0089]
- **MORRIS** J Neurosurg, 1999, vol. 91, 737-743 [0089]
- **NAKASHIMA** Anesthesiology, 1995, vol. 82, 1199-1208 [0089]
- **NIETHAMMER** J Neurosci, 1996, vol. 16, 2157-2163 [0089]
- **NOOR** Stroke, 2005, vol. 36, 665-669 [0089]
- **PAOLINO** J Neurosci Nurs, 2005, vol. 37, 130-135 [0089]
- **REGLODI** Exp Neurol, 2000, vol. 163, 399-407 [0089]
- **REITH** Lancet, 1996, vol. 347, 422-425 [0089]
- **ROBERTS-LEWIS** J Neurochem, 1993, vol. 61, 378-381 [0089]
- **ROTHMAN** Trends Neurosci, 1995, vol. 18, 57-58 [0089]
- **ROTHMAN** Trends Neurosci, 1987, vol. 10, 299-302 [0089]
- **SATTLER** Science, 1999, vol. 284, 1845-1848 [0089]
- **SCHWARZ** Science, 1999, vol. 285, 1569-1572 [0089]
- **SHENG** Proc Natl Acad Sci U S A, 2001, vol. 98, 7058-7061 [0089]
- **STAIR COMMITTEE** Stroke, 1999, vol. 30, 2752-2758 [0089]
- **WALTERS** Cerebrovasc Dis, 2005, vol. 20, 304-309 [0089]
- **WEINANDY** Lab Anim, 2005, vol. 39, 200-208 [0089]

- YEMethods Enzymol, 1996, vol. 269, 201-209 [0089]
- ZHANGScience, 1994, vol. 263, 687-689 [0089]
- ZHAOBrain Res, 1994, vol. 649, 253-259 [0089]

## PATENTKRAV

1. Peptid med en aminosyresekvens, der omfatter [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L], til anwendung ved behandling, valgfrit hvor behandlingen er profylaktisk, af den skadelige virkning af slagtilfælde forværret af feber hos et individ med feber på mindst 38 grader

5 Celsius ved påbegyndelse af behandling.
2. Peptid til anwendung ifølge krav 1, hvor feberen er på mindst 39 grader Celsius inden eller op til 24 timer efter påbegyndelse af behandling, for eksempel mellem påbegyndelse af behandling og 6 timer derefter.
- 10 3. Peptid til anwendung ifølge krav 1 eller 2, hvor [E/D/N/Q] er E, [D/E/Q/N] er D, og [V/L] er V.
- 15 4. Peptid til anwendung ifølge kravene 1 eller 2, der omfatter en aminosyresekvens, som er valgt fra gruppen bestående af ETDV, ESDV, ESEV, ETEV, DTDV og DTEV.
5. Peptid til anwendung ifølge et hvilket som helst af kravene 1 til 4, hvor peptidet omfatter ESDV eller ETDV.
- 20 6. Peptid til anwendung ifølge krav 5, hvor peptidet omfatter KLSSIETDV eller KLSSIESDV.
7. Peptid til anwendung ifølge krav 6, der omfatter eller består af en aminosyresekvens YGRKKRRQRRRKLSSIETDV eller YGRKKRRORRRKLSSIESDV.
- 25 8. Peptid til anwendung ifølge et hvilket som helst af kravene 1 til 7, hvor feberen skyldes (i) samtidig infektion, (ii) lokalitet af slagtilfældet i et område i hjernen, der indvirker på temperaturregulering eller -referencepunkt, (iii) varmeeksponering af individet.
- 30 9. Peptid til anwendung ifølge et hvilket som helst af kravene 1 til 8, hvor slagtilfældet er iskæmisk slagtilfælde.

**10.** Peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor individet også har hyperglykæmi på grund af samtidig diabetes.

**11.** Peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor behandling  
5 reducerer infarktionsvolumenet med mindst 10 %, for eksempel mindst 20 %.


**12.** Peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor individet er et  
menneske.

10 **13.** Farmaceutisk sammensætning til anvendelse ved behandling af slagtilfælde forværret af  
feber hos et individ med feber på mindst 38 grader Celsius ved påbegyndelse af behandling,  
hvilken sammensætning i enhedsdosis omfatter fra 0,05 til 500 mg, valgfrat 0,1 til 100 mg,  
for eksempel 0,5 til 50 mg såsom 1 til 20 mg, af et peptid som angivet i et hvilket som helst  
af kravene 1 eller 3 til 7.


15

**14.** Farmaceutisk sammensætning til anvendelse ifølge krav 13, hvor individet er et  
menneske.


## DRAWINGS




Sun et al., Figure 1




Sun et al., Figure 2




Sun et al., Figure 3




Sun et al., Figure 4



Sun et al., Figure 5



Sun et al., Figure 6



Sun et al., Figure 7